凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
华兰生物(002007)公告正文

华兰生物:2018年第三季度报告全文

公告日期 2018-10-30
股票简称:华兰生物 股票代码:002007
                华兰生物工程股份有限公司 2018 年第三季度报告全文




华兰生物工程股份有限公司

   2018 年第三季度报告




      2018 年 10 月




                                                              1
                                      华兰生物工程股份有限公司 2018 年第三季度报告全文




                         第一节 重要提示


    公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真

实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和

连带的法律责任。

    所有董事均已出席了审议本次季报的董事会会议。

    公司负责人安康、主管会计工作负责人谢军民及会计机构负责人(会计主管

人员)安文珏声明:保证季度报告中财务报表的真实、准确、完整。




                                                                                    2
                                                                  华兰生物工程股份有限公司 2018 年第三季度报告全文




                                       第二节 公司基本情况

一、主要会计数据和财务指标

公司是否需追溯调整或重述以前年度会计数据
□ 是 √ 否

                                       本报告期末                       上年度末               本报告期末比上年度末增减

总资产(元)                               5,746,938,975.26                5,219,312,384.50                        10.11%

归属于上市公司股东的净资产
                                           5,147,273,155.03                4,666,711,261.87                        10.30%
(元)

                                                        本报告期比上年同期                             年初至报告期末比上
                                     本报告期                                     年初至报告期末
                                                              增减                                         年同期增减

营业收入(元)                       834,759,414.86                  27.77%         2,035,902,754.03               22.19%

归属于上市公司股东的净利润
                                     306,682,234.67                  63.15%           759,588,197.16               22.69%
(元)

归属于上市公司股东的扣除非经
                                     274,955,792.76                  55.51%           679,992,109.15               19.32%
常性损益的净利润(元)

经营活动产生的现金流量净额
                                     338,515,769.38                  418.23%          720,188,318.18            2,017.02%
(元)

基本每股收益(元/股)                        0.3297                  63.14%                   0.8167               22.70%

稀释每股收益(元/股)                        0.3297                  63.14%                   0.8167               22.70%

加权平均净资产收益率                            5.79%                 1.84%                   15.05%                1.38%

非经常性损益项目和金额
√ 适用 □ 不适用
                                                                                                                  单位:元

                           项目                               年初至报告期期末金额                       说明

非流动资产处置损益(包括已计提资产减值准备的冲销部分)                         -813,369.27

计入当期损益的政府补助(与企业业务密切相关,按照国家统
                                                                           45,819,321.58
一标准定额或定量享受的政府补助除外)

除上述各项之外的其他营业外收入和支出                                       -6,573,880.63

其他符合非经常性损益定义的损益项目                                         60,805,794.82

减:所得税影响额                                                           15,108,232.08

       少数股东权益影响额(税后)                                              4,533,546.41

合计                                                                       79,596,088.01                   --

对公司根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义界定的非经常性损益项目,以及把《公
开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目,应

                                                                                                                            3
                                                                    华兰生物工程股份有限公司 2018 年第三季度报告全文


说明原因
□ 适用 √ 不适用
公司报告期不存在将根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义、列举的非经常性损益
项目界定为经常性损益的项目的情形。


二、报告期末股东总数及前十名股东持股情况表

1、普通股股东和表决权恢复的优先股股东数量及前 10 名股东持股情况表

                                                                                                               单位:股

                                                              报告期末表决权恢复的优先
报告期末普通股股东总数                               44,787                                                          0
                                                              股股东总数(如有)

                                                 前 10 名股东持股情况

                                                                      持有有限售条件          质押或冻结情况
       股东名称                  股东性质    持股比例   持股数量
                                                                        的股份数量        股份状态          数量

安康                      境内自然人           17.96% 167,017,128         125,262,846 质押                   10,500,000

重庆市晟康生物科技开
                          境内非国有法人       15.13% 140,737,784                    0 质押                  11,916,000
发有限公司

香港科康有限公司          境外法人             13.23% 123,022,541                    0

新疆世辰股权投资有限
                          境内非国有法人        3.66%    33,996,224                  0
合伙企业

中国证券金融股份有限
                          境内非国有法人        2.99%    27,810,102                  0
公司

中国银行股份有限公司
-易方达中小盘混合型      其他                  1.95%    18,163,900                  0
证券投资基金

香港中央结算有限公司      境外法人              1.60%    14,890,397                  0

中国建设银行股份有限
公司-易方达新丝路灵
                          其他                  1.45%    13,500,068                  0
活配置混合型证券投资
基金

交通银行-易方达 50 指
                          其他                  1.15%    10,709,157                  0
数证券投资基金

中央汇金资产管理有限
                          国有法人              1.15%    10,679,520                  0
责任公司

                                            前 10 名无限售条件股东持股情况

                                                                                                 股份种类
               股东名称                           持有无限售条件股份数量
                                                                                          股份种类          数量

重庆市晟康生物科技开发有限公司                                            140,737,784 人民币普通股          140,737,784


                                                                                                                          4
                                                              华兰生物工程股份有限公司 2018 年第三季度报告全文


香港科康有限公司                                                    123,022,541 人民币普通股       123,022,541

安康                                                                 41,754,282 人民币普通股        41,754,282

新疆世辰股权投资有限合伙企业                                         33,996,224 人民币普通股        33,996,224

中国证券金融股份有限公司                                             27,810,102 人民币普通股        27,810,102

中国银行股份有限公司-易方达中小盘
                                                                     18,163,900 人民币普通股        18,163,900
混合型证券投资基金

香港中央结算有限公司                                                 14,890,397 人民币普通股        14,890,397

中国建设银行股份有限公司-易方达新
                                                                     13,500,068 人民币普通股        13,500,068
丝路灵活配置混合型证券投资基金

交通银行-易方达 50 指数证券投资基金                                 10,709,157 人民币普通股        10,709,157

中央汇金资产管理有限责任公司                                         10,679,520 人民币普通股        10,679,520

                                       上述第一、二、三股东存在关联关系,属于一致行动人。中国银行股份有限公司
                                       -易方达中小盘混合型证券投资基金、中国建设银行股份有限公司-易方达新丝
上述股东关联关系或一致行动的说明       路灵活配置混合型证券投资基金和交通银行-易方达 50 指数证券投资基金同属
                                       于易方达基金管理有限公司,未知其他股东之间是否存在关联关系,是否属于一
                                       致行动人。

公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内是否进行约定购回交易
□ 是 √ 否
公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内未进行约定购回交易。


2、公司优先股股东总数及前 10 名优先股股东持股情况表

□ 适用 √ 不适用




                                                                                                                 5
                                                            华兰生物工程股份有限公司 2018 年第三季度报告全文




                                        第三节 重要事项

一、报告期主要财务数据、财务指标发生变动的情况及原因

√ 适用 □ 不适用
1. 货币资金期末余额较期初余额减少59.64%,主要系本期公司为进一步提高资金使用效率,利用闲置资金购买理财产品
     所致;
2. 其他应收款期末余额较期初余额增加135.82%,主要系期末暂付鲁山浆站土地保证金1,123.80万元所致;
3. 其他流动资产期末余额较期初余额增加38.87%,主要系本期购买理财产品增加所致;
4. 在建工程期末余额较期初余额增加42.59%,主要系本期工程项目投入增加所致;
5. 开发支出期末余额较期初余额增加599.52%,主要系本期冻干A群C群脑膜炎球菌结合疫苗项目投入增加所致;
6. 其他非流动资产期末余额较期初余额增加64.65%,主要系本期预付工程设备款增加所致;
7. 预收款项期末余额较期初余额减少30.29%,主要系本期预收货款减少所致;
8. 销售费用本报告期较上年同期增加39.43%,主要系本期推广咨询费等增加所致;
9. 财务费用本报告期较上年同期增加87.37%,主要系本期利息收入减少所致;
10. 资产减值损失本报告期较上年同期减少94.78%,主要系本期计提的坏账损失减少所致;
11. 其它收益本报告期较上年同期增加295.38%,主要系本期收到与日常经营活动相关的政府补助增加所致;
12. 营业外收入本报告期较上年同期增加168.09%,主要系本期收到其它政府补助增加所致;
13. 营业外支出本报告期较上年同期增加151.42%,主要系本公司本期对外捐赠增加所致;
14. 经营活动产生的现金流量净额本报告期较上年同期增加2,017.02%,主要系本期销售商品、提供劳务收到的现金增加所
     致;
15. 投资活动产生的现金流量净额本报告期较上年同期减少19,277.94%,主要系本期理财投入增加所致;
16. 筹资活动产生的现金流量净额本报告期较上年同期增加31.46%,主要系本期分配的现金红利减少所致。




二、重要事项进展情况及其影响和解决方案的分析说明

□ 适用 √ 不适用


三、公司实际控制人、股东、关联方、收购人以及公司等承诺相关方在报告期内超期未履行
完毕的承诺事项

□ 适用 √ 不适用
公司报告期不存在公司实际控制人、股东、关联方、收购人以及公司等承诺相关方在报告期内超期未履行完毕的承诺事项。


四、对 2018 年度经营业绩的预计

2018 年度预计的经营业绩情况:归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形

2018 年度归属于上市公司股东的净利润变动幅
                                                                 0.00%      至                       35.00%


2018 年度归属于上市公司股东的净利润变动区                     82,082.35     至                    110,811.17



                                                                                                               6
                                                              华兰生物工程股份有限公司 2018 年第三季度报告全文


间(万元)

2017 年度归属于上市公司股东的净利润(万元)                                                           82,082.35

                                               血液制品业务保持稳定增长,疫苗公司的四价流感病毒裂解疫苗 2018
业绩变动的原因说明                         年获批生产并开始销售,预计 2018 年度归属于上市公司股东的净利润与上
                                           年同期变动幅度为 0%—35%。


五、以公允价值计量的金融资产

□ 适用 √ 不适用


六、违规对外担保情况

□ 适用 √ 不适用
公司报告期无违规对外担保情况。


七、控股股东及其关联方对上市公司的非经营性占用资金情况

□ 适用 √ 不适用
公司报告期不存在控股股东及其关联方对上市公司的非经营性占用资金。


八、委托理财

√ 适用 □ 不适用
                                                                                                      单位:万元

       具体类型       委托理财的资金来源         委托理财发生额         未到期余额           逾期未收回的金额

银行理财产品         自有资金                                 5,220                  5,220                      0

信托理财产品         自有资金                                59,300               59,300                        0

券商理财产品         自有资金                                91,500               91,500                        0

合计                                                        156,020              156,020                        0

单项金额重大或安全性较低、流动性较差、不保本的高风险委托理财具体情况
□ 适用 √ 不适用
委托理财出现预期无法收回本金或存在其他可能导致减值的情形
□ 适用 √ 不适用


九、报告期内接待调研、沟通、采访等活动登记表

□ 适用 √ 不适用
公司报告期内未发生接待调研、沟通、采访等活动。




                                                                                                                    7
                                                        华兰生物工程股份有限公司 2018 年第三季度报告全文




                                     第四节 财务报表

一、财务报表

1、合并资产负债表

编制单位:华兰生物工程股份有限公司
                                       2018 年 09 月 30 日
                                                                                                  单位:元

                  项目                      期末余额                              期初余额

流动资产:

    货币资金                                             83,143,711.25                    205,992,103.92

    结算备付金

    拆出资金

    以公允价值计量且其变动计入当期
损益的金融资产

    衍生金融资产

    应收票据及应收账款                                  977,981,811.50                    939,779,272.38

      其中:应收票据                                    153,857,016.96                    161,499,151.78

               应收账款                                 824,124,794.54                    778,280,120.60

    预付款项                                             29,167,726.89                       24,417,448.29

    应收保费

    应收分保账款

    应收分保合同准备金

    其他应收款                                           19,491,309.89                        8,265,261.60

    买入返售金融资产

    存货                                               1,252,844,368.77                 1,210,879,304.15

    持有待售资产

    一年内到期的非流动资产

    其他流动资产                                       1,777,398,867.21                 1,279,903,601.85

流动资产合计                                           4,140,027,795.51                 3,669,236,992.19

非流动资产:

    发放贷款及垫款

    可供出售金融资产



                                                                                                             8
                                      华兰生物工程股份有限公司 2018 年第三季度报告全文


    持有至到期投资

    长期应收款

    长期股权投资                       73,880,778.05                     67,781,543.30

    投资性房地产

    固定资产                          903,602,038.67                    959,817,132.37

    在建工程                          272,379,309.26                    191,016,647.96

    生产性生物资产                      1,162,602.10                      1,722,519.11

    油气资产

    无形资产                          204,200,027.74                    208,728,928.49

    开发支出                            8,763,917.53                      1,252,855.44

    商誉                                1,098,329.80

    长期待摊费用                          900,244.47                      1,541,175.24

    递延所得税资产                     61,384,513.44                     69,905,095.77

    其他非流动资产                     79,539,418.69                     48,309,494.63

非流动资产合计                       1,606,911,179.75                 1,550,075,392.31

资产总计                             5,746,938,975.26                 5,219,312,384.50

流动负债:

    短期借款

    向中央银行借款

    吸收存款及同业存放

    拆入资金

    以公允价值计量且其变动计入当期
损益的金融负债

    衍生金融负债

    应付票据及应付账款                 66,540,287.11                     68,147,549.97

    预收款项                            5,318,966.83                      7,630,189.25

    卖出回购金融资产款

    应付手续费及佣金

    应付职工薪酬                        1,207,241.25                       385,745.87

    应交税费                           52,796,315.58                     51,374,863.87

    其他应付款                        294,678,474.35                    249,700,840.95

    应付分保账款

    保险合同准备金

    代理买卖证券款




                                                                                         9
                              华兰生物工程股份有限公司 2018 年第三季度报告全文


    代理承销证券款

    持有待售负债

    一年内到期的非流动负债

    其他流动负债

流动负债合计                  420,541,285.12                    377,239,189.91

非流动负债:

    长期借款

    应付债券

      其中:优先股

               永续债

    长期应付款

    长期应付职工薪酬

    预计负债

    递延收益

    递延所得税负债

    其他非流动负债

非流动负债合计

负债合计                      420,541,285.12                    377,239,189.91

所有者权益:

    股本                      930,087,680.00                    930,087,680.00

    其他权益工具

      其中:优先股

               永续债

    资本公积                  394,523,232.03                    394,523,232.03

    减:库存股

    其他综合收益

    专项储备

    盈余公积                  454,799,984.48                    454,799,984.48

    一般风险准备

    未分配利润               3,367,862,258.52                 2,887,300,365.36

归属于母公司所有者权益合计   5,147,273,155.03                 4,666,711,261.87

    少数股东权益              179,124,535.11                    175,361,932.72

所有者权益合计               5,326,397,690.14                 4,842,073,194.59

负债和所有者权益总计         5,746,938,975.26                 5,219,312,384.50



                                                                            10
                                                                 华兰生物工程股份有限公司 2018 年第三季度报告全文


法定代表人:安康                       主管会计工作负责人:谢军民                        会计机构负责人:安文珏


2、母公司资产负债表

                                                                                                           单位:元

                   项目                              期末余额                              期初余额

流动资产:

    货币资金                                                      15,426,680.18                    125,081,152.38

    以公允价值计量且其变动计入当期损
益的金融资产

    衍生金融资产

    应收票据及应收账款                                           449,591,285.32                    537,893,824.41

      其中:应收票据                                              85,463,552.83                    135,470,602.62

               应收账款                                          364,127,732.49                    402,423,221.79

    预付款项                                                     130,121,603.54                       75,072,498.86

    其他应收款                                                    13,729,109.00                       13,803,076.05

    存货                                                         509,050,949.37                    548,093,025.85

    持有待售资产

    一年内到期的非流动资产

    其他流动资产                                                1,327,000,000.00                   924,200,000.00

流动资产合计                                                    2,444,919,627.41                 2,224,143,577.55

非流动资产:

    可供出售金融资产

    持有至到期投资

    长期应收款

    长期股权投资                                                 766,881,675.16                    735,802,440.41

    投资性房地产

    固定资产                                                     387,700,439.28                    418,471,533.84

    在建工程                                                      82,516,667.86                       76,573,920.79

    生产性生物资产

    油气资产

    无形资产                                                     122,630,777.87                    125,531,074.46

    开发支出

    商誉

    长期待摊费用                                                     900,244.47                        1,241,341.50




                                                                                                                  11
                                        华兰生物工程股份有限公司 2018 年第三季度报告全文


    递延所得税资产                        6,718,140.76                      6,658,413.36

    其他非流动资产                       29,651,369.76                      6,419,811.68

非流动资产合计                         1,396,999,315.16                 1,370,698,536.04

资产总计                               3,841,918,942.57                 3,594,842,113.59

流动负债:

    短期借款

    以公允价值计量且其变动计入当期损
益的金融负债

    衍生金融负债

    应付票据及应付账款                   36,055,495.49                     48,208,306.33

    预收款项                              3,156,901.40                      3,819,916.40

    应付职工薪酬                            979,776.66                       156,336.00

    应交税费                             26,318,735.10                     30,777,036.87

    其他应付款                           82,064,470.07                     38,857,582.46

    持有待售负债

    一年内到期的非流动负债

    其他流动负债

流动负债合计                            148,575,378.72                    121,819,178.06

非流动负债:

    长期借款

    应付债券

      其中:优先股

               永续债

    长期应付款

    长期应付职工薪酬

    预计负债

    递延收益

    递延所得税负债

    其他非流动负债

非流动负债合计

负债合计                                148,575,378.72                    121,819,178.06

所有者权益:

    股本                                930,087,680.00                    930,087,680.00

    其他权益工具




                                                                                      12
                                                   华兰生物工程股份有限公司 2018 年第三季度报告全文


      其中:优先股

            永续债

    资本公积                                        403,271,029.54                     403,271,029.54

    减:库存股

    其他综合收益

    专项储备

    盈余公积                                        454,799,984.48                     454,799,984.48

    未分配利润                                    1,905,184,869.83                 1,684,864,241.51

所有者权益合计                                    3,693,343,563.85                 3,473,022,935.53

负债和所有者权益总计                              3,841,918,942.57                 3,594,842,113.59


3、合并本报告期利润表

                                                                                             单位:元

                 项目              本期发生额                             上期发生额

一、营业总收入                                  834,759,414.86                         653,354,606.76

    其中:营业收入                              834,759,414.86                         653,354,606.76

          利息收入

          已赚保费

          手续费及佣金收入

二、营业总成本                                  509,659,626.12                         445,399,685.81

    其中:营业成本                              308,974,698.10                         257,922,440.54

          利息支出

          手续费及佣金支出

          退保金

          赔付支出净额

          提取保险合同准备金净额

          保单红利支出

          分保费用

          税金及附加                              6,864,747.03                           5,777,888.02

          销售费用                              120,995,505.31                         102,815,253.84

          管理费用                               43,912,026.00                          40,623,822.73

          研发费用                               28,659,689.65                          41,528,392.07

          财务费用                                 253,161.05                           -3,268,111.39

            其中:利息费用                        1,775,346.16



                                                                                                   13
                                            华兰生物工程股份有限公司 2018 年第三季度报告全文


                      利息收入             1,628,511.94                         3,326,489.76

             资产减值损失                       -201.02

       加:其他收益                       17,884,521.58                         3,028,585.00

           投资收益(损失以“-”号填
                                          24,831,972.70                         5,231,245.52
列)

             其中:对联营企业和合营
                                           2,909,636.07                        -3,156,650.51
企业的投资收益

           公允价值变动收益(损失以
“-”号填列)

           汇兑收益(损失以“-”号填
列)

           资产处置收益(损失以“-”号
                                            -174,385.52                          -412,484.14
填列)

三、营业利润(亏损以“-”号填列)       367,641,897.50                       215,802,267.33

       加:营业外收入                      1,259,936.84                         3,536,338.26

       减:营业外支出                      2,499,574.53                          441,267.30

四、利润总额(亏损总额以“-”号填
                                         366,402,259.81                       218,897,338.29
列)

       减:所得税费用                     50,521,567.85                        33,120,714.77

五、净利润(净亏损以“-”号填列)       315,880,691.96                       185,776,623.52

       (一)持续经营净利润(净亏损
                                         315,880,691.96                       183,748,605.65
以“-”号填列)

       (二)终止经营净利润(净亏损
                                                                                2,028,017.87
以“-”号填列)

       归属于母公司所有者的净利润        306,682,234.67                       187,978,209.67

       少数股东损益                        9,198,457.29                        -2,201,586.15

六、其他综合收益的税后净额

  归属母公司所有者的其他综合收益
的税后净额

       (一)不能重分类进损益的其他
综合收益

             1.重新计量设定受益计划
变动额

             2.权益法下不能转损益的
其他综合收益

       (二)将重分类进损益的其他综
合收益



                                                                                          14
                                                               华兰生物工程股份有限公司 2018 年第三季度报告全文


             1.权益法下可转损益的其
他综合收益

             2.可供出售金融资产公允
价值变动损益

             3.持有至到期投资重分类
为可供出售金融资产损益

             4.现金流量套期损益的有
效部分

             5.外币财务报表折算差额

             6.其他

  归属于少数股东的其他综合收益的
税后净额

七、综合收益总额                                            315,880,691.96                         185,776,623.52

       归属于母公司所有者的综合收益
                                                            306,682,234.67                         187,978,209.67
总额

       归属于少数股东的综合收益总额                           9,198,457.29                          -2,201,586.15

八、每股收益:

       (一)基本每股收益                                          0.3297                                 0.2021

       (二)稀释每股收益                                          0.3297                                 0.2021

本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:0.00 元,上期被合并方实现的净利润为:0.00 元。


法定代表人:安康                      主管会计工作负责人:谢军民                       会计机构负责人:安文珏


4、母公司本报告期利润表

                                                                                                         单位:元

                 项目                          本期发生额                             上期发生额

一、营业收入                                                392,416,336.82                         408,679,868.60

       减:营业成本                                         136,449,725.88                         152,056,615.01

           税金及附加                                         2,536,143.85                           2,553,875.27

           销售费用                                          50,647,984.62                          19,271,878.79

           管理费用                                          16,989,931.57                          16,175,375.26

           研发费用                                          14,918,859.90                          18,744,281.45

           财务费用                                            265,053.09                           -2,091,834.58

             其中:利息费用                                   1,104,955.73

                      利息收入                                 852,262.51                            2,138,841.06

           资产减值损失



                                                                                                               15
                                            华兰生物工程股份有限公司 2018 年第三季度报告全文


       加:其他收益                       15,794,733.58

           投资收益(损失以“-”号填
                                          22,482,569.98                        78,684,994.25
列)

           其中:对联营企业和合营企
                                           2,909,636.07                        -3,156,650.51
业的投资收益

           公允价值变动收益(损失以
“-”号填列)

           资产处置收益(损失以“-”号
                                             -29,303.40                           -49,143.09
填列)

二、营业利润(亏损以“-”号填列)       208,856,638.07                       280,605,528.56

       加:营业外收入                       167,909.00                           300,000.00

       减:营业外支出                      2,015,497.78                          237,786.15

三、利润总额(亏损总额以“-”号填
                                         207,009,049.29                       280,667,742.41
列)

       减:所得税费用                     31,487,802.80                        31,323,658.94

四、净利润(净亏损以“-”号填列)       175,521,246.49                       249,344,083.47

       (一)持续经营净利润(净亏损
                                         175,521,246.49                       249,344,083.47
以“-”号填列)

       (二)终止经营净利润(净亏损
以“-”号填列)

五、其他综合收益的税后净额

       (一)不能重分类进损益的其他
综合收益

             1.重新计量设定受益计划
变动额

             2.权益法下不能转损益的
其他综合收益

       (二)将重分类进损益的其他综
合收益

             1.权益法下可转损益的其
他综合收益

             2.可供出售金融资产公允
价值变动损益

             3.持有至到期投资重分类
为可供出售金融资产损益

             4.现金流量套期损益的有
效部分

             5.外币财务报表折算差额


                                                                                          16
                                                        华兰生物工程股份有限公司 2018 年第三季度报告全文


             6.其他

六、综合收益总额                                     175,521,246.49                         249,344,083.47

七、每股收益:

       (一)基本每股收益

       (二)稀释每股收益


5、合并年初到报告期末利润表

                                                                                                  单位:元

                 项目                   本期发生额                             上期发生额

一、营业总收入                                   2,035,902,754.03                       1,666,195,575.88

       其中:营业收入                            2,035,902,754.03                       1,666,195,575.88

             利息收入

             已赚保费

             手续费及佣金收入

二、营业总成本                                   1,236,852,193.21                       1,016,386,078.59

       其中:营业成本                                788,326,182.94                         618,481,997.81

             利息支出

             手续费及佣金支出

             退保金

             赔付支出净额

             提取保险合同准备金净额

             保单红利支出

             分保费用

             税金及附加                               19,052,665.68                          17,325,633.92

             销售费用                                224,528,744.24                         161,036,614.97

             管理费用                                125,317,647.30                         121,371,104.34

             研发费用                                 80,205,744.20                          93,894,890.49

             财务费用                                 -1,366,776.00                         -10,818,917.28

               其中:利息费用                          2,529,255.31

                      利息收入                         4,124,097.21                          10,888,288.67

             资产减值损失                               787,984.85                           15,094,754.34

       加:其他收益                                   17,884,521.58                           4,523,321.00

           投资收益(损失以“-”号填
                                                      66,905,029.57                          59,540,898.17
列)



                                                                                                        17
                                            华兰生物工程股份有限公司 2018 年第三季度报告全文


           其中:对联营企业和合营企
                                           6,099,234.75                        10,960,895.82
业的投资收益

           公允价值变动收益(损失以
“-”号填列)

           汇兑收益(损失以“-”号填
列)

           资产处置收益(损失以“-”号
                                            -813,369.27                          -552,935.94
填列)

三、营业利润(亏损以“-”号填列)       883,026,742.70                       713,320,780.52

       加:营业外收入                     27,971,829.06                        10,433,693.37

       减:营业外支出                      6,610,909.69                         2,629,443.81

四、利润总额(亏损总额以“-”号填
                                         904,387,662.07                       721,125,030.08
列)

       减:所得税费用                    141,036,862.52                       111,521,223.63

五、净利润(净亏损以“-”号填列)       763,350,799.55                       609,603,806.45

       (一)持续经营净利润(净亏损
                                         763,350,799.55                       607,637,468.86
以“-”号填列)

       (二)终止经营净利润(净亏损
                                                                                1,966,337.59
以“-”号填列)

       归属于母公司所有者的净利润        759,588,197.16                       619,098,693.73

       少数股东损益                        3,762,602.39                        -9,494,887.28

六、其他综合收益的税后净额

  归属母公司所有者的其他综合收益
的税后净额

       (一)不能重分类进损益的其他
综合收益

             1.重新计量设定受益计划
变动额

             2.权益法下不能转损益的
其他综合收益

       (二)将重分类进损益的其他综
合收益

             1.权益法下可转损益的其
他综合收益

             2.可供出售金融资产公允
价值变动损益

             3.持有至到期投资重分类
为可供出售金融资产损益


                                                                                          18
                                                               华兰生物工程股份有限公司 2018 年第三季度报告全文


             4.现金流量套期损益的有
效部分

             5.外币财务报表折算差额

             6.其他

  归属于少数股东的其他综合收益的
税后净额

七、综合收益总额                                            763,350,799.55                         609,603,806.45

       归属于母公司所有者的综合收益
                                                            759,588,197.16                         619,098,693.73
总额

       归属于少数股东的综合收益总额                           3,762,602.39                          -9,494,887.28

八、每股收益:

       (一)基本每股收益                                          0.8167                                 0.6656

       (二)稀释每股收益                                          0.8167                                 0.6656

本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:0.00 元,上期被合并方实现的净利润为:0.00 元。


6、母公司年初到报告期末利润表

                                                                                                         单位:元

                 项目                          本期发生额                             上期发生额

一、营业收入                                            1,124,746,017.05                       1,051,397,510.83

       减:营业成本                                         410,873,519.40                         400,519,230.11

           税金及附加                                         7,581,493.85                           7,273,722.86

           销售费用                                         107,336,886.81                          45,054,646.21

           管理费用                                          49,986,848.01                          49,889,453.96

           研发费用                                          30,813,236.19                          47,595,994.14

           财务费用                                            -808,512.06                          -7,915,628.87

             其中:利息费用                                   1,858,864.88

                      利息收入                                2,683,891.87                           7,918,572.74

           资产减值损失                                        398,182.64                           10,627,366.81

       加:其他收益                                          15,794,733.58

           投资收益(损失以“-”号填
                                                             57,769,334.83                         126,791,777.24
列)

           其中:对联营企业和合营企
                                                              6,099,234.75                          10,960,895.82
业的投资收益

           公允价值变动收益(损失以
“-”号填列)




                                                                                                               19
                                            华兰生物工程股份有限公司 2018 年第三季度报告全文


           资产处置收益(损失以“-”号
                                             -54,346.22                           -82,411.35
填列)

二、营业利润(亏损以“-”号填列)       592,074,084.40                       625,062,091.50

       加:营业外收入                       979,909.00                           450,201.10

       减:营业外支出                      5,711,755.90                         1,240,422.72

三、利润总额(亏损总额以“-”号填
                                         587,342,237.50                       624,271,869.88
列)

       减:所得税费用                     87,995,305.18                        80,745,272.47

四、净利润(净亏损以“-”号填列)       499,346,932.32                       543,526,597.41

       (一)持续经营净利润(净亏损
                                         499,346,932.32                       543,526,597.41
以“-”号填列)

       (二)终止经营净利润(净亏损
以“-”号填列)

五、其他综合收益的税后净额

       (一)不能重分类进损益的其他
综合收益

             1.重新计量设定受益计划
变动额

             2.权益法下不能转损益的
其他综合收益

       (二)将重分类进损益的其他综
合收益

             1.权益法下可转损益的其
他综合收益

             2.可供出售金融资产公允
价值变动损益

             3.持有至到期投资重分类
为可供出售金融资产损益

             4.现金流量套期损益的有
效部分

             5.外币财务报表折算差额

             6.其他

六、综合收益总额                         499,346,932.32                       543,526,597.41

七、每股收益:

       (一)基本每股收益

       (二)稀释每股收益




                                                                                          20
                                                    华兰生物工程股份有限公司 2018 年第三季度报告全文


7、合并年初到报告期末现金流量表

                                                                                              单位:元

               项目                 本期发生额                             上期发生额

一、经营活动产生的现金流量:

     销售商品、提供劳务收到的现金            1,903,363,187.01                       1,151,969,787.81

     客户存款和同业存放款项净增加


     向中央银行借款净增加额

     向其他金融机构拆入资金净增加


     收到原保险合同保费取得的现金

     收到再保险业务现金净额

     保户储金及投资款净增加额

     处置以公允价值计量且其变动计
入当期损益的金融资产净增加额

     收取利息、手续费及佣金的现金

     拆入资金净增加额

     回购业务资金净增加额

     收到的税费返还

     收到其他与经营活动有关的现金                120,751,910.01                          38,478,143.46

经营活动现金流入小计                         2,024,115,097.02                       1,190,447,931.27

     购买商品、接受劳务支付的现金                562,848,227.20                         589,512,681.47

     客户贷款及垫款净增加额

     存放中央银行和同业款项净增加


     支付原保险合同赔付款项的现金

     支付利息、手续费及佣金的现金

     支付保单红利的现金

     支付给职工以及为职工支付的现
                                                 219,843,784.26                         176,435,570.30


     支付的各项税费                              227,773,879.72                         192,004,923.94

     支付其他与经营活动有关的现金                293,460,887.66                         198,475,865.62

经营活动现金流出小计                         1,303,926,778.84                       1,156,429,041.33

经营活动产生的现金流量净额                       720,188,318.18                          34,018,889.94

二、投资活动产生的现金流量:


                                                                                                    21
                                           华兰生物工程股份有限公司 2018 年第三季度报告全文


       收回投资收到的现金             4,729,806,983.81                     4,633,770,000.00

       取得投资收益收到的现金           60,805,794.82                         48,580,002.35

       处置固定资产、无形资产和其他
                                           592,363.67                             94,703.33
长期资产收回的现金净额

       处置子公司及其他营业单位收到
的现金净额

       收到其他与投资活动有关的现金

投资活动现金流入小计                  4,791,205,142.30                     4,682,444,705.68

       购建固定资产、无形资产和其他
                                       129,444,820.99                        120,619,302.12
长期资产支付的现金

       投资支付的现金                 5,227,306,983.81                     4,524,750,000.00

       质押贷款净增加额

       取得子公司及其他营业单位支付
                                         1,179,948.74                         40,000,000.00
的现金净额

       支付其他与投资活动有关的现金

投资活动现金流出小计                  5,357,931,753.54                     4,685,369,302.12

投资活动产生的现金流量净额             -566,726,611.24                        -2,924,596.44

三、筹资活动产生的现金流量:

       吸收投资收到的现金

       其中:子公司吸收少数股东投资
收到的现金

       取得借款收到的现金

       发行债券收到的现金

       收到其他与筹资活动有关的现金

筹资活动现金流入小计

       偿还债务支付的现金

       分配股利、利润或偿付利息支付
                                       272,136,692.11                        397,035,072.00
的现金

       其中:子公司支付给少数股东的
股利、利润

       支付其他与筹资活动有关的现金

筹资活动现金流出小计                   272,136,692.11                        397,035,072.00

筹资活动产生的现金流量净额             -272,136,692.11                      -397,035,072.00

四、汇率变动对现金及现金等价物的
                                            18,923.23                              2,461.85
影响

五、现金及现金等价物净增加额           -118,656,061.94                      -365,938,316.65



                                                                                         22
                                                    华兰生物工程股份有限公司 2018 年第三季度报告全文


     加:期初现金及现金等价物余额                197,867,498.39                         473,365,713.13

六、期末现金及现金等价物余额                      79,211,436.45                         107,427,396.48


8、母公司年初到报告期末现金流量表

                                                                                              单位:元

               项目                 本期发生额                             上期发生额

一、经营活动产生的现金流量:

     销售商品、提供劳务收到的现金            1,158,082,823.98                           700,557,626.33

     收到的税费返还

     收到其他与经营活动有关的现金                 53,146,554.86                          12,783,154.05

经营活动现金流入小计                         1,211,229,378.84                           713,340,780.38

     购买商品、接受劳务支付的现金                321,578,959.92                         345,807,705.15

     支付给职工以及为职工支付的现
                                                  75,458,046.56                          43,087,834.23


     支付的各项税费                              134,595,506.57                         100,274,185.00

     支付其他与经营活动有关的现金                102,726,652.84                          93,604,699.08

经营活动现金流出小计                             634,359,165.89                         582,774,423.46

经营活动产生的现金流量净额                       576,870,212.95                         130,566,356.92

二、投资活动产生的现金流量:

     收回投资收到的现金                      3,938,026,983.81                       3,441,000,000.00

     取得投资收益收到的现金                       51,670,100.08                         115,830,881.42

     处置固定资产、无形资产和其他
                                                                                             59,800.00
长期资产收回的现金净额

     处置子公司及其他营业单位收到
的现金净额

     收到其他与投资活动有关的现金

投资活动现金流入小计                         3,989,697,083.89                       3,556,890,681.42

     购建固定资产、无形资产和其他
                                                  37,030,054.04                          40,173,486.02
长期资产支付的现金

     投资支付的现金                          4,340,826,983.81                       3,443,200,000.00

     取得子公司及其他营业单位支付
                                                  24,880,000.00                          40,000,000.00
的现金净额

     支付其他与投资活动有关的现金

投资活动现金流出小计                         4,402,737,037.85                       3,523,373,486.02

投资活动产生的现金流量净额                   -413,039,953.96                             33,517,195.40



                                                                                                    23
                                          华兰生物工程股份有限公司 2018 年第三季度报告全文


三、筹资活动产生的现金流量:

       吸收投资收到的现金

       取得借款收到的现金

       发行债券收到的现金

       收到其他与筹资活动有关的现金

筹资活动现金流入小计

       偿还债务支付的现金

       分配股利、利润或偿付利息支付
                                      271,466,301.68                        372,035,072.00
的现金

       支付其他与筹资活动有关的现金

筹资活动现金流出小计                  271,466,301.68                        372,035,072.00

筹资活动产生的现金流量净额            -271,466,301.68                      -372,035,072.00

四、汇率变动对现金及现金等价物的
                                           19,380.65                             38,065.36
影响

五、现金及现金等价物净增加额          -107,616,662.04                      -207,913,454.32

       加:期初现金及现金等价物余额   122,634,035.89                        243,839,885.94

六、期末现金及现金等价物余额           15,017,373.85                         35,926,431.62


二、审计报告

第三季度报告是否经过审计
□ 是 √ 否
公司第三季度报告未经审计。




                                                        华兰生物工程股份有限公司



                                                                董事长:安康



                                                               2018年10月29日




                                                                                        24
数据加载中...
prevnext
手机查看股票